vTv grants GLP-1r agonist diabetes program rights in China to Hangzhou Zhongmei

This article was originally published here

vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical for rights to develop and commercialize the former’s GLP-1r agonist program in China and other Pacific Rim countries.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply